SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Description: 

The primary objectives are to determine the maximum tolerated dose (MTD), or the maximum tested dose where multiple dose-limiting toxicities (DLTs) are not observed, of SL-401, and to characterize the safety profile of SL-401 at the MTD or maximum tested dose.

Study Number: 

PH 259514

Phase: 
Early Phase
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02113982

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.